Pharma CEO Guide to Regulatory Affairs Operations
Regulatory affairs is the function that translates your scientific work into an approved product. It is also, for many pharma CEOs, the least understood and most underinvested operational domain in the company. That imbalance creates real risk: regulatory setbacks are among the most expensive and demoralizing events a pharmaceutical company can experience, and many of them are operationally preventable.
This guide is written for pharma CEOs who want to engage more strategically with regulatory affairs, not as technical experts, but as operational leaders who understand how regulatory strategy integrates with development planning, how agency relationships are built and protected, and how regulatory operations capacity connects directly to approval timelines.
Why Regulatory Affairs Is a CEO-Level Priority
Regulatory affairs sits at the intersection of science, law, and operations. A well-run regulatory function accelerates the path to approval by ensuring submissions are complete, agency relationships are productive, and the development program anticipates and addresses regulatory requirements proactively. A poorly run regulatory function creates delays, generates complete response letters (CRLs) that can set a program back by years, and damages the agency relationships that are critical to a company’s long-term success.
The financial stakes are significant. A six-month delay in regulatory approval for a product with $500 million in annual revenue potential costs roughly $250 million in foregone revenue. A CRL that requires an additional clinical study can cost significantly more. These are not abstract risks. They are the direct consequence of regulatory operations that lack rigor.
As CEO, you cannot delegate regulatory strategy the way you might delegate IT infrastructure. The regulatory pathway for your lead program should be a topic you engage with directly, alongside your CMO and Chief Regulatory Officer (CRO), at regular intervals throughout the development process.
The Organizational Foundation of Regulatory Affairs
Building the Right Team
Regulatory affairs requires a unique combination of scientific literacy, legal rigor, strategic thinking, and interpersonal sophistication. Great regulatory professionals are not simply scientists who write documents. They are strategists who understand how agencies think, how submissions are evaluated, and how to navigate the gray areas in regulatory guidance.
As CEO, ensure that your regulatory function is led by someone with the right profile: ideally a person with direct FDA (or EMA, if you are pursuing European approval) experience, a track record of successful submissions, and the confidence to push back on unrealistic timelines or shortcuts that would compromise submission quality.
The regulatory leader should have a seat at the senior leadership table and direct access to the CEO. Regulatory affairs decisions are rarely purely technical. They are strategic decisions with financial, operational, and reputational implications. Embedding regulatory leadership in the C-suite ensures those decisions are made with the full organizational context.
Regulatory Operations Infrastructure
Beyond the strategic function, regulatory affairs requires operational infrastructure: document management systems, regulatory information management (RIM) tools, submission management processes, and a cross-functional review and approval workflow for key regulatory documents.
Many emerging pharma companies underinvest in regulatory operations infrastructure, relying instead on improvised document management and manual submission assembly processes. This approach is manageable for a single small submission but breaks down quickly when multiple programs are in development, submissions need to be coordinated globally, or agency correspondence needs to be tracked systematically.
Invest in regulatory operations infrastructure early. The cost of building it proactively is a fraction of the cost of rebuilding it under pressure in the middle of a critical submission.
Regulatory Strategy: The CEO’s Engagement Points
Program-Level Strategy
Every development program should have a documented regulatory strategy that is aligned with the development plan and reviewed at least annually. The regulatory strategy should address: the target label, the required studies to support that label, the regulatory pathway (standard review, priority review, breakthrough designation, accelerated approval), the agency interaction plan, and the key risks and contingencies.
The CEO should understand the regulatory strategy for each program in the portfolio at a high level. You do not need to understand every technical nuance. You need to understand: What regulatory pathway are we pursuing and why? What are the risks to that pathway? What would trigger a strategy change? How does the regulatory strategy interact with our commercial positioning?
When your regulatory team presents a program update, ask about these dimensions explicitly. Your engagement signals that regulatory strategy is an organizational priority, not just a compliance function.
Agency Interaction Strategy
Agency interactions, including Type A, B, and C meetings with the FDA and equivalent meetings with other global agencies, are high-stakes strategic touchpoints. How your organization prepares for and conducts these meetings has a direct impact on the quality of agency feedback and the trust that agencies have in your organization.
Every significant agency meeting should have a meeting request that is strategically framed, a briefing document that clearly articulates the questions you want answered, and a preparation process that involves cross-functional alignment before the meeting.
The CEO does not typically attend agency meetings. But the CEO should know what meetings are scheduled, what the key questions are, and what outcomes are expected. After each significant agency interaction, require a debrief that covers what was learned and what adjustments to the program strategy are needed.
Breakthrough Designation and Expedited Programs
The FDA offers several expedited programs for drugs that address serious unmet medical needs: Fast Track designation, Breakthrough Therapy designation, Accelerated Approval, and Priority Review. Each has different eligibility criteria, different operational implications, and different relationships with the agency.
Breakthrough Therapy designation, in particular, is one of the most valuable regulatory tools available to an emerging pharma company. It enables more intensive FDA guidance during development, rolling review of submission modules, and organizational commitment from senior FDA staff to work collaboratively with the sponsor. According to research published in the Journal of Clinical Pharmacology and summarized by McKinsey, Breakthrough designation has been associated with meaningfully faster approval timelines.
As CEO, ensure your regulatory team is actively evaluating each program’s eligibility for expedited designations and submitting requests where the case can be made. This is a strategic decision with potentially enormous value, not a technical formality.
Submission Quality and the Submission Excellence Model
Regulatory submissions, particularly NDAs, BLAs, and MAAs, are among the most complex and consequential documents your organization will produce. The quality of those submissions directly influences how quickly the agency can review them, how many information requests you receive, and whether the review cycle ends in approval or a CRL.
Submission quality depends on three things: the quality of the underlying clinical and nonclinical data, the quality of the regulatory writing and documentation, and the operational rigor of the submission assembly and review process.
Build a submission excellence model that establishes quality standards for each component. Define who reviews and approves each section of a major submission. Establish timelines for internal review cycles that are realistic for the document volume involved. Run mock submissions or internal audits before major submission dates to identify gaps before the agency sees them.
Regulatory writing is a specialized skill. If your internal team does not have sufficient capacity or expertise for a major submission, engage regulatory writing consultants with specific submission experience. The cost is small relative to the risk of a preventable submission deficiency.
Global Regulatory Operations
If your programs have global commercial potential, your regulatory strategy needs to address multiple markets from early in development. The requirements of the FDA, EMA, PMDA (Japan), and other major agencies differ in ways that affect clinical program design, data requirements, and submission timelines.
Global regulatory strategy is best addressed at the program design stage. Retrofitting a U.S.-only development program to meet global requirements is expensive and time-consuming. Building global requirements into the development plan from the start is operationally efficient and commercially strategic.
As CEO, ensure your regulatory team has either the internal expertise or the external advisory relationships to guide global regulatory strategy. If you are planning commercial operations in major markets outside the U.S., global regulatory capability is not optional.
Risk Management in Regulatory Affairs
Regulatory risk is a significant component of your overall development portfolio risk. Managing it requires identifying the key risks early, building mitigation strategies into the development plan, and monitoring the risk landscape as programs advance.
The most common regulatory risks in drug development include: unclear regulatory pathway; insufficient efficacy or safety data to support the target label; manufacturing quality issues that create CMC (chemistry, manufacturing, and controls) concerns; and agency disagreements about study design or endpoints.
Build a regulatory risk register for each program that is reviewed quarterly alongside clinical and financial risk. Map each risk to a mitigation strategy and track the status of those mitigations. When risks escalate, bring them to the CEO and board proactively rather than after they have materialized.
For a comprehensive review of the operational systems that support your regulatory and clinical functions, see the pharma operations checklist.
Post-Approval Regulatory Operations
Approval is not the end of your regulatory obligations. It is the beginning of a different set of obligations: pharmacovigilance and safety reporting, label management, post-marketing commitments, and lifecycle management submissions.
Post-approval regulatory operations require dedicated infrastructure and capacity. Many companies underinvest here because the urgency of pre-approval submissions dominates attention. The result is post-marketing commitments that slip, safety reporting systems that are not robust enough, and label updates that are delayed.
Build post-approval regulatory operations into your organizational planning before you receive approval, not after. Integrate pharmacovigilance into your broader risk management framework. Establish a lifecycle management committee that reviews post-approval regulatory strategy at regular intervals.
For additional guidance on the quality systems that underpin post-approval operations, see pharma manufacturing quality.
Building Agency Trust as an Organizational Asset
Agency relationships are organizational assets that take years to build and can be damaged quickly. The FDA and other regulatory agencies form opinions of sponsors based on the quality of their submissions, the accuracy of their commitments, the responsiveness of their teams, and the integrity of the data they present.
As CEO, you carry responsibility for the organizational reputation that underlies these relationships. Set clear expectations internally: communications with agencies are factual and complete; commitments made to agencies are met; and when problems arise, they are disclosed proactively rather than managed reactively.
The CEOs who build the best agency relationships are those who create a culture of regulatory integrity where no one on the team would consider presenting data selectively or making commitments the organization cannot keep. That culture starts at the top.
Conclusion
Regulatory affairs operations is one of the highest-leverage functions a pharma CEO can invest in strategically. The difference between a regulatory function that accelerates programs to approval and one that creates delays and surprises often comes down to organizational design, resource investment, strategic engagement, and cultural standards.
Your role is not to be the regulatory expert. It is to ensure that regulatory strategy is integrated with development planning, that your regulatory team has the authority and resources to do the work, that agency relationships are managed as organizational assets, and that regulatory risk is visible and managed at the senior leadership level.
Build the infrastructure. Engage the strategy. Protect the integrity. The path to approval runs through regulatory affairs, and the CEO who understands that builds the competitive advantage that defines market leadership.
Related Reading
For further context, explore Pharma CEO Guide to Business Development Operations and Pharma CEO Guide to Business Operations Management.